CD19 targeting T cell engager therapy (Candid Therapeutics)

N/A

Report date: 2025/03/12 10:27:31

Base Information

Drug NameCD19 targeting T cell engager therapy (Candid Therapeutics)
Drug Alias NameTrispecific T cell engager therapy
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWuxi Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCandid Therapeutics IncWuxi Biologics Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A